NDA 020415 · Organon
Remeron
Mirtazapine · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jul 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Jun 14, 1996
Approved uses
2
Original approval plus efficacy supplements
Registered trials
127
25 Phase 3, 7 recruiting
FAERS reports
93,069
77,961 serious, 14,287 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . REMERON/REMERONSolTab is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. REMERON/REMERONSolTab is not approved for use in pediatric patients. ( 5.1 , 8.4 )
What it is approved for
From the label in effect Aug 6, 2025.
REMERON/REMERONSolTab are indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies (14) ] . REMERON/REMERONSolTab is indicated for the treatment of major depressive disorder (MDD) in adults. ( 1 )
Mechanism: The mechanism of action of mirtazapine for the treatment of major depressive disorder, is unclear. However, its efficacy could be mediated through its activity as an antagonist at central presynaptic α 2 -adrenergic inhibitory autoreceptors and heteroreceptors and enhancing central noradrenergic and serotonergic activity.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 9, 2002 Supplement 9 · Efficacy Letter
- Jun 14, 1996 Original approval · Type 1 - New Molecular Entity Other Important Information from FDAReview
3 products under this application
- REMERON · MIRTAZAPINE 30MG · TABLET, ORAL · Prescription · TE AB
- REMERON · MIRTAZAPINE 45MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- REMERON · MIRTAZAPINE 15MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Mirtazapine" as an intervention, any sponsor and status, largest first.
- Sequenced Treatment Alternatives to Relieve Depression (STAR*D)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00021528 · 4,000 participants · Start Jul 2001
Drug: citalopram; BuproprionSR and 8 more · For: Depression
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Chula Vista, California · 41 sites in all
- Strategic Use of New Generation Antidepressants for DepressionPivotal-lookingCompleted
Kyoto UniversityAcademic, hospital or other
NCT01109693 · 2,011 participants · Start Dec 2010 · Primary completion Sep 2015
Drug: Sertraline; Mirtazapine · For: Unipolar Major Depressive Episode
Sites: Nagoya, Japan; Nangoku, Japan
- VA Augmentation and Switching Treatments for Improving Depression OutcomesPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT01421342 · 1,522 participants · Start Dec 2012 · Primary completion Aug 2015
Drug: Switching: Bupropion-SR; Augmenting: Antidepressant + Bupropion-SR and 1 more · For: Major Depressive Disorder
Sites: Tuscaloosa, Alabama; Phoenix, Arizona; Tucson, Arizona · 35 sites in all
- Algorithm Guided Treatment Strategies for Major Depressive DisorderPivotal-lookingStatus unknown
Shanghai Mental Health CenterAcademic, hospital or other
NCT01764867 · 1,080 participants (planned) · Start Jun 2012 · Primary completion Oct 2014
Drug: Escitalopram; Mirtazapine and 11 more · For: Major Depressive Disorder
Sites: Shanghai, China
Samsung Medical CenterAcademic, hospital or other
NCT00817011 · 1,000 participants (planned) · Start Apr 2006 · Primary completion Dec 2016
Drug: SSRI treated group; non-SSRI treated group · For: Depression; Antidepressant Drug Adverse Reaction
Sites: Kangnam, South Korea
- Prediction of Antidepressant Response Using Pharmacogenetics and Peripheral Lymphocytic PhenotypeStatus unknown
Samsung Medical CenterAcademic, hospital or other
NCT01352559 · 1,000 participants (planned) · Start Nov 2001 · Primary completion Mar 2007
Drug: responders; non-responders · For: Depression
Sites: Kangnam, South Korea
Samsung Medical CenterAcademic, hospital or other
NCT01228357 · 1,000 participants (planned) · Start Feb 2003 · Primary completion Dec 2018
Drug: SSRI treated group; non-SSRI treated group · For: Depression; Depressive Symptoms
Sites: Kangnam, South Korea
Samsung Medical CenterAcademic, hospital or other
NCT00817375 · 1,000 participants (planned) · Start Feb 2003 · Primary completion Dec 2018
Drug: SSRI treated group; non-SSRI treated group · For: Depression; Adverse Reaction to Drug
Sites: Kangnam, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea5,124
- fatigue5,006
- drug ineffective4,903
- fall4,248
- diarrhoea4,175
- off label use4,082
- toxicity to various agents3,985
- dizziness3,670
- anxiety3,652
- dyspnoea3,602
- death3,521
- drug interaction3,468
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,058 |
| 2005 | 1,207 |
| 2006 | 1,307 |
| 2007 | 1,300 |
| 2008 | 1,305 |
| 2009 | 1,892 |
| 2010 | 2,234 |
| 2011 | 2,590 |
| 2012 | 2,748 |
| 2013 | 2,527 |
| 2014 | 3,087 |
| 2015 | 4,008 |
| 2016 | 4,596 |
| 2017 | 5,114 |
| 2018 | 6,608 |
| 2019 | 7,303 |
| 2020 | 7,212 |
| 2021 | 6,131 |
| 2022 | 6,330 |
| 2023 | 6,409 |
| 2024 | 6,273 |
| 2025 | 6,720 |
| 2026 | 5,107 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Remeron (Mirtazapine)
2024 spending
$732K
Beneficiaries
465
2,169 claims
Per beneficiary
$1,573
$5.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $136,560 |
| 2022 | $756,226 |
| 2023 | $790,626 |
| 2024 | $731,560 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A, Furukawa TA, Salanti G, et al. · Lancet 2018 · Comparative Study, Research Support, Non-U.S. Gov't
- Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
Nuñez NA, Joseph B, Pahwa M, et al. · J Affect Disord 2022 · Network Meta-Analysis, Research Support, N.I.H., Extramural
- Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Rush AJ, Fava M, Wisniewski SR, et al. · Control Clin Trials 2004 · Clinical Trial, Multicenter Study
- Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis.
Slee A, Nazareth I, Bondaronek P, et al. · Lancet 2019 · Systematic Review, Network Meta-Analysis
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Drug-drug interactions with warfarin: A systematic review and meta-analysis.
Wang M, Zeraatkar D, Obeda M, et al. · Br J Clin Pharmacol 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Organon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.